NORCROSS, Ga., Jan. 19 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today it has received a purchase order for 8 Galileo systems from Blood Systems Laboratories.
Blood Systems Laboratories specializes in high volume blood donor testing. Their two national laboratories test more than 2.6 million blood donations each year for more than 75 blood and tissue collection sites. Blood Systems Laboratories is a national leader in donor testing services and will use Immucor’s Galileo instrument for antibody screening and blood typing.
“Blood Systems Laboratories is one of the largest donor testing laboratories in the United States,” stated Dr. Gioacchino De Chirico, President of Immucor, Inc. “We are very pleased that this prestigious laboratory has selected Galileo.”
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at www.immucor.com.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor’s expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as “plans,” “expects,” “believes,” “anticipates,” “estimates,” “projects,” “will,” “should” and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements. Our financial results may be adversely impacted by the inability of customers, including Blood Systems Laboratories, to effectively integrate our Galileo instruments into their blood testing operations. Further risks are detailed in the Company’s filings with the Securities and Exchange Commission. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.
CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com//